We have developed an algorithm called Q5 for probabilistic classi cation of healthy versus disease whole serum samples using mass spectrometry. The algorithm employs principal components analysis (PCA) followed by linear discriminant analysis (LDA) on whole spectrum surface-enhanced laser desorption/ionization time of ight (SELDI-TOF) mass spectrometry (MS) data and is demonstrated on four real datasets from complete, complex SELDI spectra of human blood serum. Q5 is a closed-form, exact solution to the problem of classi cation of complete mass spectra of a complex protein mixture. Q5 employs a probabilistic classi cation algorithm built upon a dimension-reduced linear discriminant analysis. Our solution is computationally ef cient; it is noniterative and computes the optimal linear discriminant using closed-form equations. The optimal discriminant is computed and veri ed for datasets of complete, complex SELDI spectra of human blood serum. Replicate experiments of different training/testing splits of each dataset are employed to verify robustness of the algorithm. The probabilistic classi cation method achieves excellent performance. We achieve sensitivity, speci city, and positive predictive values above 97% on three ovarian cancer datasets and one prostate cancer dataset. The Q5 method outperforms previous full-spectrum complex sample spectral classi cation techniques and can provide clues as to the molecular identities of differentially expressed proteins and peptides.
INTRODUCTION
¤ M ass Spectrometry (MS) is a powerful tool for determining the masses of biomolecules and biomolecular fragments present in a complex sample mixture. The role of MS is similar to that 1. Q5 is a combinatorially precise algorithm: we can prove that the training runtime is O.n 3 C n 2 r/ and the testing runtime is O.mrn/, where n is the number of training spectra, m is the number of testing spectra, and r is the resolution of each mass spectrum. 2. Q5 always computes the optimal solution (with respect to the error function) using closed-form equations.
For exact algorithms such as ours, properties (1) and (2) can be proven mathematically. Hence, one can formally understand and analyze why a technique performs well, or poorly. We caution however, that exact does not necessarily imply perfect performance on biological data: it means the algorithm is guaranteed to optimize an objective error criterion that measures how well the (noisy) data is classi ed. In contrast, techniques such as genetic algorithms (Petricoin et al., 2002) , neural networks (Ball et al., 2002; Goodacre et al., 1998) , and simulated annealing do not admit such guarantees: these methods have neither provable complexity nor correctness properties, and they are neither exact nor combinatorially precise.
¤ Abbreviations used: BPH, benign prostatic hypertrophy; CFES, closed-form exact solution; LDA, linear discriminant analysis; MALDI, matrix-assisted laser desorption/ionization; MS, mass spectrometry; MSCA, mass spectrometry classi cation algorithm; OC, ovarian cancer; PC, prostate cancer; PCA, principal components analysis; PPV, positive predictive value; PSA prostate speci c antigen; SELDI-TOF, surface-enhanced laser desorption/ionization time of ight.
FIG. 1.
Major steps of the Q5 algorithm. The steps involved in building a two-class classi er are illustrated using simpli ed arti cial spectra. On the left are training (£, ±) and testing ( , 4) spectra. Shown on the right, from top to bottom, are (1) the spectral space representation of each spectrum; (2) PCA: the result of dimensionality reduction (for simplicity we show the projection onto just the top two principle components); (3) LDA: the projection of each spectrum onto the discriminant surface H ; and (4) the probabilistic classi cation. In this example, the testing spectrum denoted by is classi ed as belonging to the class denoted by ±, while the spectrum denoted by 4 is unclassi ed.
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testing were ovarian and prostate cancer. Existing screening methods for both cancers carry a low positive predictive value (PPV) (Jacobs et al., 1999; Catalona et al., 1994) . When detected early, the ve-year survival rate increases for both cancers (SEER, 2002) . Improved screening techniques would be welcomed by the biomedical community.
Previous work
An MSCA accepts as input a set of MS training spectra, together with their correct classi cations. It outputs a classi er (discriminant) capable of classifying new mass spectra into one of the classes. These new spectra (called test spectra) have not been seen by the algorithm before, and their classi cations are unknown to the algorithm; the goal of the MSCA is to determine the correct classi cation based on the classi er constructed from the training set. Classi cation veri cation is the testing process by which the discriminant is evaluated for its ability to correctly classify test samples. MSCAs can be classi ed by the type of MS data processed, type of algorithm employed, and method of classi cation veri cation used. In the remainder of this section, we rst describe a framework in which MSCAs can be compared. We then review previous work utilizing this framework. Finally, we summarize the key differences between previous work and Q5.
Completeness of mass spectrum. Analysis may be performed on either complete or partial mass spectra. Complete mass spectra consist of the relative intensities of all m=z values acquired during MS data collection. This includes the relative intensities observed for all m=z values from 0 up to the upper limit of detection. An MSCA that processes complete mass spectra works with the entire recorded spectra: no values are "manually" excluded through preprocessing. When portions of a spectrum are excluded from consideration, we say a partial spectrum is generated.
Manual preprocessing. Frequently, spectra are manually preprocessed. In manual preprocessing, parts of the spectrum may be eliminated from consideration based on the magnitude of the relative intensity or prior (human) knowledge. This spectral manipulation produces a manually processed partial spectrum. Modi cation of the peak intensities in a manner that imparts additional information represents another type of manual manipulation.
Sample source (the biological source of the MS sample). Spectra may be obtained from either simple or complex fragment mixtures. Simple mixtures may contain one or only a small number of proteins and usually yield relatively "clean" spectra with fewer peaks. Complex fragment mixtures contain between tens to thousands of biological fragments and produce a commensurate number of m=z peaks. These peaks often present a challenge to MS analysis algorithms: a particular m=z peak may be the sum of many subpeaks (contributions) from many different molecular fragments. Human serum (used in our application) is, for example, a complex fragment mixture.
Heuristic versus exact classi cation algorithms. Heuristic classi cation algorithms include approaches such as genetic algorithms, neural networks, and simulated annealing. These algorithms generally require multiple iterations to converge to a classi er; furthermore, the solution found by heuristic algorithms is not guaranteed to be optimal. In addition, many heuristic approaches are nondeterministic. Even when run on the same training set, the same nondeterministic algorithm often converges to a different discriminant. In contrast, MSCAs that utilize closed-form exact solutions (CFES) compute an exact solution using closedform equations. CFES algorithms are computationally ef cient; they are noniterative and deterministic (i.e., always compute the same solution). Linear discriminant analysis (LDA), and thus Q5, are CFES algorithms.
Classi cation veri cation. Classi cation algorithms must be veri ed, to con rm that the discriminant will properly classify samples that were not used in training. To test a classi cation algorithm, it is essential to perform multiple leave-out experiments, each with a different split between the training and testing (masked) sets. Often, there exists a split of samples into training and testing sets that perform signi cantly better than others. The performance statistics of the classi er against multiple different splits must therefore be reported. When only one or a small number of splits are tested, classi cation veri cation is said to be partial.
The use of a testing set also allows one to con rm that the discriminant has not been over-t to the training data. If the discriminant has been over t to the training spectra then one would expect excellent performance in the classi cation of the training spectra but poor performance in the classi cation of the testing spectra.
We now describe speci c examples of existing MSCAs in previous research. Each example is discussed using the framework introduced above. We then describe Q5's advantages over previous techniques.
Heuristic classi cation techniques. Petricoin et al. (2002) give a heuristic MSCA on complete complex spectra with classi cation veri cation. The method employs a genetic algorithm to select between 5 and 20 m=z peaks for use in classi cation. This MSCA was applied to SELDI 1 -TOF spectra of blood serum from 100 women with ovarian cancer, 100 women without cancer, and 17 women with benign gynecological disease. A genetic algorithm was trained on a set of spectra containing half of the cancer spectra and half of the normal spectra. The remaining 117 spectra were used in testing. A single training/testing split was performed; a sensitivity of 100%, speci city of 95%, and PPV of 94% was reported. Petricoin and coworkers have recently tested their MSCA against two additional sets of ovarian cancer and one set of prostate cancer SELDI mass spectra (NIH, 2002) .
Adam et al. developed a decision tree based heuristic MSCA on partial complex spectra with partial classi cation veri cation for the diagnosis of prostate cancer (Adam et al., 2002) . A training set containing 85% of the total samples (n D 326) was used to build the decision tree. The MSCA started with a subset of 124 MS peaks and built a three-class decision tree using 9 of these. Partial testing using a single training/testing split resulted in a sensitivity of 83%, speci city of 97%, and PPV of 96%.
Another heuristic MSCA based on discriminant factorial analysis has been used to discriminate between betamethasone and dexamethasone (Antignac et al., 2002) . Discriminant factorial analysis is an iterative technique that attempts to converge to the answer directly computed by LDA. Additionally, while not truly MSCAs, a number of papers have reported on heuristic techniques for the identi cation of differentially expressed m=z peaks. Arti cial neural networks have been used to identify m=z peaks associated with astrocytoma (Ball et al., 2002) as well as bacteria involved in urinary tract infections (Goodacre et al., 1998) .
Exact classi cation algorithms. Two recent works applied LDA to MS analysis. Miketova et al. (2003) performed LDA on a subset of peaks to differentiate Gram positive versus Gram negative bacteria. They present an exact algorithm on manually processed partial complex spectra without classi cation veri cation. Their analysis used reduced dimensionality electron ionization mass spectra containing the relative intensities of 36 hand-picked m=z values. These 36 values surrounded 12 low-resolution mass peaks that had been shown in previous work to have discriminating power. The linear discriminant was computed on a training set of 36 sample spectra (18 Gram positive and 18 Gram negative). Although the computed discriminant was able to separate the training samples, its ability to classify novel samples was not evaluated. Wagner et al. (2002) present an exact algorithm on manually processed partial simple spectra with classi cation veri cation. They performed TOF-SIMS (time-of-ight secondary ion MS) on a small number of proteins (12), each prepared as a single protein adsorbed lm using one of two substrates. Replicate experiments were performed which generated spectra covering only the single amino-acid mass range of 0-200 m=z. Analysis was performed using two sets of peaks: the rst set consisted of a preselected peak list while the second set contained all peaks with an intensity at least three times greater than the 0-200 m=z background region. They compared the discriminating power of principal components analysis (PCA), discriminant principal component analysis (DPCA), and LDA. Leave-one-out experiments were performed on multiple training/testing splits. The linear discriminant was used to predict the identity of an unknown single protein adsorbed lm from its mass spectrum. Among their results, they showed that LDA and DPCA provide better discriminating power than PCA. Goodacre et al. (1999) performed LDA on the electrospray ionization (ESI) mass spectra collected from three replicates of six different bacteria. Partial spectra from 100-3,050 m=z were used in analysis and no classi cation veri cation was performed. That is, no test spectra were classi ed using the computed discriminant.
In summary, of the existing MSCAs, those that use complete complex spectra (Petricoin et al., 2002; Adam et al., 2002) do not use exact algorithms. Conversely, those MSCAs that are exact do not operate on 930 LILIEN ET AL. complete complex spectra (Miketova et al., 2003; Wagner et al., 2002) . Moreover, only partial classi cation veri cation results have been reported for essentially all existing MSCAs. In these respects, Q5 differs from all previous MSCAs. Whereas Petricoin et al. and Adam et al. used heuristic methods, Q5 uses LDA, an exact method. In contrast to the work of Miketova et al. and Wagner et al. we do not remove from consideration parts of the recorded mass spectrum based on relative intensity or a priori (human) knowledge. Our work utilizes af nity chip ltered human serum containing tens to thousands of proteins and protein fragments. Q5 uses complete mass spectra, sampled at 15,154 (respectively, 16,382 ) m=z values over the range 0-20,000 (respectively, 0-22,500), to compute a discriminant for ovarian (respectively, prostate) cancer datasets. Whereas Wagner et al. classi ed unknown spectra by assigning them to the nearest class, we employ a novel probabilistic classi cation framework. For each unclassi ed testing spectrum, Q5 computes both the most likely class assignment as well as the probability that the unknown spectrum belongs to the speci ed class. Whereas only partial classi cation veri cation has been reported on existing MSCAs, Q5 is tested with several thousand training/testing splits. Q5 is, to our knowledge, the rst closedform exact solution to the problem of probabilistically classifying complete mass spectra of a complex protein mixture. Finally, Q5 employs a discriminant back-projection algorithm to compute clues as to the molecular identities of differentially expressed proteins and peptides.
METHODS
We have designed and implemented Q5 to classify complex samples from mass spectrometry data. The major steps of Q5 are illustrated in Fig. 1 . In our algorithm, each spectrum is represented by a point in spectral-space, as described above. The set of all spectral points in spectral-space is dimensionality reduced using principal components analysis (PCA) (Duda and Hart, 1973) . In particular, PCA performs a transformation of spectral-space into a lower dimensional space with little or no information loss. A hyperplane, H , is then computed using linear discriminant analysis (LDA) (Fisher, 1936; Duda and Hart, 1973) . The PCA dimensionality-reduced sample points are projected onto H . The hyperplane H maximizes the across-class variance while minimizing the within-class variance of the projected sample points (Fisher, 1936) . Thus, the LDA-computed hyperplane H satis es our exactness criterion. As a result, classi cation is made easier in this projected space. Now, suppose we wish to classify some new (test) spectra (that were not used in training). A test spectrum is rst dimensionality reduced by projecting onto the retained principal components. Next, it is projected onto the hyperplane H . Finally, if the classi cation con dence is above a threshold, then the point is classi ed into the healthy or disease state. The con dence in classi cation is based on a symmetric Gaussian distribution centered at each class mean. The process of classifying two test spectra, represented by and 4, is illustrated in Fig. 1 .
The three spaces used by Q5 are spectral-space, PCA-space, and discriminant-space. Spectral-space has been described above. PCA-space is the space spanned by the principal components retained from the PCA dimensionality reduction; discriminant-space H is the space spanned by the linear discriminant(s) computed from LDA. Discriminant-space has lower dimensionality than PCA-space, which has lower dimensionality than spectral-space.
Principal components analysis
Principal component analysis (PCA) is often used in the analysis of points that are embedded in a highdimensional space. PCA is a method for determining orthogonal axes of maximal variance from a dataset (Duda and Hart, 1973) . PCA is an unsupervised technique: the classi cation of each sample point is not considered in analysis. Sample points are zero-meaned, and an eigendecompositionof the covariance matrix is computed. The eigenvector associated with the i th largest eigenvalue lies along the i th principal component. Typically most sample point variance is captured by the rst few principal components, (i.e., those with the largest eigenvalues). Projecting a dataset onto these largest principal components reduces sample dimensionality while maximally preserving variance. PCA is used by Q5 for dimensionality reduction: it is not, and should not, be used to compute a linear separator directly. For example, the projections of the sample points onto the rst principal component are overlapping (as will be shown below in Figs. 6A and 6B) and are not classi able. PCA is used in Q5 only to reduce the dimensionality of the sample points (with little or no information loss), as is required by LDA. See Appendix A for details.
Linear discriminant analysis
Linear discriminant analysis (LDA) (Fisher, 1936; Duda and Hart, 1973 ) of a system with k classes in d dimensions computes, in closed-form, k ¡ 1 orthogonal vectors, each of dimension d, which specify a hyperplane of dimension k¡1. Projection of the sample points onto this hyperplane maximizes the betweenclass scatter and minimizes the within-class scatter (Fig. 6C ). For the purposes of sample classi cation, such a projection is clearly desirable, because it simultaneously reduces the dimensionality of the data and preserves the ability to discriminate one class from another. Whereas other discriminant-based approaches (e.g., discriminant factorial analysis (DFA)) attempt to converge to the optimal separator through multiple iterations (Antignac et al., 2002) , LDA computes the optimal discriminant directly in closed form.
2 LDA is a supervised technique: the class membership of each sample is utilized in computing the discriminant. See Appendix B for details.
Back-projection
The LDA-computed linear discriminant can be back-projected from a PCA-space discriminant into a spectral-space discriminant. A spectral-space discriminant allows one to determine the m=z values of peaks used to differentiate between members of the two classes. This information is in principle useful in determining the molecular identities of differently expressed biomolecules. The spectral-space linear discriminant, e ² , can be computed from the PCA-space linear discriminant, e, by left-multiplying by the transpose of the principle component matrix, V ( Equation 8):
To determine which m=z values of the discriminant contribute most to classi cation, the spectral-space discriminant should be normalized by the average intensity of the zero-meaned spectra. Thus, an r-dimensional signi cance vector s can be computed, with components
where N y is the average cancer spectrum, ¹ 0 is the all-class mean (Equation 3), and r is the dimensionality of spectral-space. Each s i thus represents the signi cance of the i th m=z value of the mass spectrum for classi cation.
Probabilistic classi cation
In the simplest case, a novel sample is classi ed into the class with the closest class mean. However, if the sample spectrum's projection into discriminant space is nearly equidistant to two or more class means, then the con dence of classi cation should be reduced. Thus, a classi er should report not only the classi cation of a given sample but also the con dence in that classi cation. A probabilistic framework for reporting classi cation likelihoods was therefore implemented in Q5. The classi cation probability of each spectrum is computed from the distance in discriminant-space between the spectrum and the nearest class mean. See Appendix C for details.
Q5 testing
The testing of Q5 against each dataset consists of D-experiments and D-runs. In the rst step of a D-experiment (Fig. 2) , the set of all n sample spectra is randomly partitioned into a training set T and a testing (masked) set M. Following this partition, Q5 performs PCA on the spectral points in set T .
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FIG. 2. One D-experiment.
A complete complex spectral dataset is rst partitioned into training and testing sets. A PCA basis is then computed from the training spectra. These spectra are projected (denoted by ¼ ) onto the PCA basis creating the PCA-space representation. The spectra in this space are then projected onto the computed LDA discriminant. The class means and Gaussian probability distribution standard deviations, ¾ are computed from this representation. In the testing stage, the testing spectra are rst projected onto the PCA basis, then onto the LDA discriminant, and then classi ed.
The result of PCA is that each spectrum is now a point in the (n ¡ 3)-dimensional PCA-space. The optimal separating hyperplane is next computed using LDA on the PCA dimensionality-reduced training spectra. The discriminant-space sample points from each class should be inherently clustered. The center of each cluster is then computed and used in probabilistic classi cation. A spectrum with a probability of classi cation less than a xed threshold is not classi ed by Q5. A collection of s D-experiments is called a D-run. For each of the four datasets, four D-runs are performed with training sets consisting of 50%, 75%, 85%, and 95% of the total samples. For example, the 75% D-Run consists of s D-experiments; in each D-experiment a different random 75% of the total samples is assigned to the training set and the remaining 25% is assigned to the testing set. To illustrate the robustness of Q5, s D 1,000 D-experiments were performed in each D-run. For each D-experiment, the percent classi ed, percent correctly classi ed, positive predictive value, sensitivity, and speci city were computed using probability classi cation thresholds evenly sampled between 0.5 and 1.0. The mean and standard deviation of these values are computed for each D-run.
Algorithmic complexity
Let n be the number of training spectra, m be the number of testing spectra, r be the resolution of each mass spectrum, and k be the number of classes. PCA requires computing the top n eigenvectors of the covariance matrix C built from the training spectra (Equation 5). The eigenvectors of C can be computed ef ciently using the n £ n Gram matrix (Equation 6 ). The Gram matrix C 0 can be constructed in O.n 2 r/ time and its eigenvectors computed in O.n 3 / time. Computing the eigenvectors of C from the eigenvectors of C 0 then requires O.n 2 r/ time. Projection of the training spectra onto the PCA basis requires O.n 2 r/ time. Computing the LDA discriminant entails computing the generalized eigenvectors of the .n ¡ 3/ £ .n ¡ 3/ within-and between-class scatter matrices (Equations 10 and 11). This can be done in time O.n 3 /. Projection onto the discriminant requires O.kn/ time. Finally, since each spectrum can appear in at most one cluster, computing the class means requires O.n/ amortized time. Therefore, training can be accomplished in time O.n 3 C n 2 r/. The testing of m sample spectra can be performed in O.mrn C mnk C mk 2 / time: The all-class training mean can be subtracted in O.r/ time. Projection onto the PCA basis is O.rn/ time; projection onto the LDA discriminant is O.nk/ time. The nearest cluster mean is computed in time O.k 2 /, and the classi cation probability computed in time O.1/. In our studies, k · 3 and r¸15,154. Since we expect k ¿ r, if we assume k D O.1/, the testing of one spectrum can be performed in time O.rn/, and m spectra can be classi ed in time O.mrn/. The PCA and LDA computations on the training set require 1.0 to 1.5 minutes of runtime on a Pentium 4 class workstation. Classi cation of a novel sample can be performed in under a second.
Implementation
Datasets were obtained from the NIH and FDA Clinical Proteomics Program Databank (2002) and the Eastern Virginia Medical School (2002) . Each spectrum in these datasets is contained in either an individual or a grouped le and is separated into either a healthy or a disease subdirectory. These data les are in either comma-delimited or Microsoft Excel format. Data le reading, PCA, LDA, and probabilistic classi cation are implemented in MATLAB (Mathworks Inc, Natick, MA).
Each D-run is processed separately by Q5: the speci ed dataset is loaded and 1,000 D-experiments are performed each with a random training/testing split. For each D-experiment, the training sample mean and discriminant-space projections of both the training and testing spectra are computed and saved. Subsequently, Q5 computes the PPV, sensitivity, speci city, percent correct, and percent classi ed for each D-experiment. These statistics are a function of the threshold used in probabilistic classi cation. Statistics were therefore computed for probability classi cation thresholds evenly spaced between 0.5 and 1.0 (see Figs. 3 and 4) .
RESULTS AND DISCUSSION
Q5 was applied to classify three ovarian cancer and one prostate cancer dataset. In this section, we report on the performance of the Q5 algorithm and compare these results, where possible, to previous MSCAs.
All datasets are complete complex spectra from SELDI-TOF MS experiments. Datasets were provided by Dr. Emanuel Petricoin III and Dr. George Wright Jr. The Petricoin group MS spectra were obtained from the NIH and FDA Clinical Proteomics Program Databank (2002) . The Wright group MS spectra were obtained from the Eastern Virginia Medical School, Virginia Prostate Center (2002). We named each dataset by the cancer type screened (ovarian cancer (OC) or prostate cancer (PC)) and the SELDI af nity chip used in MS (H4 (hydrophobic), WCX2 (weak cation exchange, negative), or IMAC-Cu (immobilized metal af nity capture, coated with CuSO 4 )). The healthy samples in the ovarian cancer datasets come from women at risk for ovarian cancer (the demographic most likely to use and bene t from serum screening), while the ovarian cancer positive samples come from women with tumors spanning all major epithelial subtypes and stages of disease. The samples from both OC-H4 and OC-WCX2a were manually prepared; the OC-WCX2b samples were prepared by a robotic instrument. Serum samples in the prostate cancer dataset (Adam et al., 2002) were collected and processed manually from men with normal prostates, benign prostatic hypertrophy, and all four stages of prostate cancer. The IMAC-3 af nity chip was coated with CuSO 4 and used in the SELDI MS experiment. All SELDI chips are produced by Ciphergen Biosystems (Freemont, CA, USA). The baseline was subtracted by the labs preparing the datasets OC-H4, OC-WCX2a, and PC-IMACCu; this results in some m=z peaks having negative relative intensities. The Petricoin group normalized the relative intensities of each sample in dataset OC-WCX2b to lie between 0 and 100. We performed no additional preprocessing on these datasets. The datasets are sampled at 15,154 (respectively, 16,382) m=z values over the range 0-20,000 (respectively, 0-22,500). All m=z points and relative intensities in the collected spectra are used in Q5 spectral analysis; none are discarded. Further details of the datasets are given in Table 1 and have been described previously (Petricoin et al., 2002; NIH, 2002; Adam et al., 2002) .
The initial dimensionality of spectral-space (15,154 for the ovarian cancer spectra (NIH, 2002) , 16,382 for the prostate cancer spectra (Eastern Virginia Medical School, 2002) ) is typically larger than the intrinsic dimensionality of the training set. Although the complete training spectra exist in 15,154-or 16,382-dimensional space, the intrinsic dimensionality of these points is bounded by the number of training samples. LDA cannot be performed on a set of points in a space with dimensionality larger than the set's intrinsic dimensionality. That is, in order to guarantee a nondegenerate solution for LDA, the dimensionality of the data must be reduced to at most n ¡ k where n is the number of samples and k is the number of classes (Fisher, 1936) . Therefore, since the intrinsic dimensionality of the training samples is no more than 95% of the total number of samples (327 in the largest dataset) we must project the spectra into a lower dimensional space. For this reason, PCA is performed on each training set. We use the n ¡ 3 largest principal components in dimensionality reduction since both two-and three-class LDA experiments are performed.
We now describe the results of running Q5 on the four datasets. Q5 achieves performance results that compare favorably to previous work. For all datasets, a number of the training/testing splits result in 100% classi cation accuracy.
Ovarian cancer. Q5 was applied to the three ovarian cancer datasets (OC-H4, OC-WCX2a, and OCWCX2b). The results of this analysis are given in Table 2 and Fig. 3 . For each dataset, a D-run was performed with training sets consisting of 50%, 75%, 85%, and 95% of the total number of sample spectra. Thus, a total of 12,000 D-experiments were performed across these 12 D-runs. As one increases the probability classi cation threshold, the percent classi ed decreases. At the same time, increasing the threshold increases the percent correctly classi ed, sensitivity, speci city, and positive predictive value. Thus, a higher threshold allows for increased classi cation accuracy at the cost of a decreased number of samples classi ed. A classi cation threshold exists that allows Q5 to classify 90.0% of the OC-H4 samples with a PPV of 97.4%, a sensitivity of 97.5%, and a speci city of 96.8%. Q5 achieves better performance statistics on the WCX datasets. Q5 can classify 93.4% of the OC-WCX2a samples with a PPV of 99.2%, a sensitivity of 98.8%, and a speci city of 98.9%. Q5's best performance is achieved on the OC-WCX2b dataset; classi cation is perfect in all 3,000 D-experiments beyond the 50% training level. That is, 100% of the samples are classi ed with a PPV of 100%, a sensitivity of 100%, and a speci city of 100%. It is worth noting that for each dataset tested, there exists a probability classi cation threshold which achieves perfect classi cation in a majority of the D-experiments. The variance in classi cation performance illustrates the importance of reporting MSCA results on multiple different train/test splits. Prostate cancer. Q5 was then tested against the PC-IMAC-Cu prostate cancer dataset. Q5 was used to compute both a two-and three-class discriminant. Each sample in the PC-IMAC-Cu dataset is classi ed as either normal healthy (NH), benign prostatic hypertrophy (BPH), or prostate cancer (PC). For the twoclass discriminant tests, both NH and BPH samples were considered "healthy" while PC samples were considered "disease." The two-class discriminant tests consist of four D-runs performed with training sets containing 50%, 75%, 85%, and 95% of the total number of sample spectra. As in the ovarian cancer tests, each D-run of the prostate cancer tests consisted of 1,000 D-experiments. The percent classi ed, percent correctly classi ed, positive predictive value, sensitivity, and speci city are reported in Table 3 and Figs. 4A and 4B. One set of three-class experiments was performed. In the three-class experiment, each sample was classi ed as either NH, BD, or PC (Table 4) . Similarly to the other datasets, 4 D-runs were performed with training sets containing 50%, 75%, 85%, and 95% of the total number of sample spectra. The results of the three-class experiments are shown in Table 4 and Figs. 4C and 4D. As was the case with the ovarian cancer classi cation, the prostate cancer classi cation showed a tradeoff between the accuracy and the percent of samples classi ed. In the two-class experiments, Q5 was able to classify 85.6% of the PC-IMAC-Cu samples with a PPV of 94.3%, a sensitivity of 91.3%, and a speci city of 93.0%. In the three-class experiments, Q5 classi ed 92.0% of the samples with a positive predictive value of 96.1%, a sensitivity of 93.2%, and a speci city of 96.1%. If we allow only 67.1% of samples to be classi ed, Q5 achieves a PPV of 99.2%, a sensitivity of 98.1%, and a speci city of 99.3%. Table 5 shows three-way classi cation results.
For comparison, we forced Q5 to classify 100% of the training spectra. In this experiment, each spectrum was classi ed into the class with the nearest class mean. The results of classifying 100% of the samples for each training percent are shown in the top row of each training percent in Tables 3 and 4 . This "complete" classi cation achieves an accuracy approximately equal to that obtained using a 0.5 probability classi cation threshold. We note that these accuracies are not as high as those achieved when a larger probability classi cation threshold is used. This illustrates that increased predictive accuracy can be achieved by not classifying "ambiguous" spectra.
To verify that the discriminant computed by Q5 is not overly sensitive to outliers, we retrained the classi er for the ovarian cancer dataset OC-H4 using 75% of the data for training and misclassi ed 5% of this data in the training stage. With a probability classi cation threshold of 0.5, we are able to classify 97.80% of the testing data: 87.74% is correctly classi ed, with a PPV of 88.60%, a sensitivity of 86.82%, and a speci city of 88.65%. This compares reasonably well to the result with perfectly classi ed training PROBABILISTIC DISEASE CLASSIFICATION 935 FIG. 3. The probability classi cation threshold versus percent classi ed (Classif), percent correctly classi ed (Correct), positive predictive value (PPV), sensitivity (Sens), and speci city (Spec) for six D-runs of Q5 on the ovarian cancer datasets. (A) OC-H4, 50% of samples used in training, (B) OC-H4, 95% of samples used in training, (C) OC-WCX2a, 50% of samples used in training, (D) OC-WCX2a, 95% of samples used in training, (E) OC-WCX2b, 50% of samples used in training, (F) OC-WCX2b, 95% of samples used in training. Increased probability classi cation thresholds increase Q5's percent correctly classi ed, positive predictive value, sensitivity, and speci city while decreasing the percent classi ed. Performance on the robotically prepared OC-WCX2b dataset is near perfect; see Table 2 .
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data for the same dataset, where we are able to classify 98.60% of the testing data: 92.20% is correctly classi ed, with a PPV of 92.13%, a sensitivity of 92.45%, and a speci city of 91.95% (see Table 2 ). We conclude that a small number of misclassi ed training samples has only a small effect on overall performance. One reason for this is that LDA relies on the variance of the projected data, and for a signi cantly large enough training set, a small number of outliers will not have a particularly adverse effect.
The consistency of the computed discriminants for each dataset was examined. Each discriminant is back-projected (Section 2.3) from PCA-space into spectral-space. The dot product between all pairs of discriminants was computed. The normalized discriminants for each experiment fall within a small region of the 15,154-or 16,382-dimension unit-hypersphere (results not shown). This represents an advantage of Q5 over nondeterministic methods in that the Q5 computed discriminants are similar for all D-experiments. Petricoin et al. (2002) report classi cation statistics for only one training/testing split of the OC-H4 dataset; no performance statistics have been published for the OC-WCX2a and OC-WCX2b datasets. This makes a comprehensive comparison of Q5 to previous work dif cult. The reported performance of the Petricoin group MSCA (on the OC-H4 dataset) lies within one standard deviation of the mean performance statistics of Q5. Q5 classi cation results on the OC-WCX2a and OC-WCX2b datasets were near perfect. There are, however, no published performance results of MSCAs on these datasets to which the Q5 results can be directly compared.
Comparison of results to other MSCAs
Q5's prostate cancer classi cation results can be compared to those of Adam et al. (2002) , who performed a single testing/training split and achieved a sensitivity of 83%, speci city of 97%, and PPV of 96%. Q5 achieved a higher sensitivity and a similar speci city and PPV (Tables 3 and 4) . Additionally, in a threeway experiment, the decision tree of Adam et al. reports 100% of the normal healthy samples as normal, 93% of the BPH samples as BPH, and 83% of the PC samples as PC. Q5's three-way classi cation results are better: Q5 detects a higher percentage of prostate cancer samples among those it is able to classify (Table 5) . Hence, Q5 outperformed the decision-tree based prostate cancer MSCA.
For the datasets tested, Q5 is able to determine that spectral differences do indeed exist between the healthy and disease states. These spectral differences are a function of molecular differences existing between the two sets of samples. Q5's LDA-computed discriminant provides the m=z values of peaks differentially present between the two states. Thus, Q5 is able to provide full answers to questions I) and IIa) posed in the introduction (Section 1). In summary, we found that Q5 classi cation performed at or above the level of existing MSCAs. It is worth noting that all existing MSCAs reviewed here, including Q5, outperform the currently used clinical CA125 and PSA tests. The future for MSCAs in analyzing human blood serum appears promising.
Back-projection
All MSCAs assume that some m=z peaks are differentially observed between the healthy and disease classes. Identi cation of m=z peaks with large class-speci c relative intensity differences can, in principle, allow for the identi cation of biomolecules affected by the disease process. Most heuristic MSCAs base classi cation on a small number of m=z peaks. For example, Petricoin et al. (2002) use 5-20 m=z peaks and Adam et al. (2002) use 9 m=z peaks. Thus, information on class-speci c relative intensity differences for most m=z peaks is not available. An advantage of LDA is that the spectral-space discriminant can be used to compute a classi cation signi cance for all m=z values (Section 2.3, Equation 2). Below, we show how to query a protein database using the discriminant peaks. The discriminant can also serve as supporting evidence for biomarkers discovered via other experimental techniques: the SELDI mass spectrum of a hypothesized serum biomarker can be checked for consistency with a discriminant.
To test the power of the back-projected discriminant for determining the identities of differently expressed proteins and peptides, we took the largest m=z peaks from the normalized discriminant (the signi cance vector), interpreted them as masses, and looked up those masses in two protein databases (Table 6 ). While the lookup is likely to yield some false positives due to mass-aliasing, the database lookup for the ovarian (respectively, prostate) queries found 27 (respectively, 39) proteins and peptide fragments that have been implicated in other human cancers, are growth factors, or are known serum or plasma proteins. While FIG. 4 . The probability classi cation threshold versus percent classi ed (Classif), percent correctly classi ed (Correct), positive predictive value (PPV), sensitivity (Sens), and speci city (Spec) for two D-runs of Q5 on the PC-IMAC-Cu dataset. (A) 2-Class LDA, 50% of samples used in training, (B) 2-Class LDA, 95% of samples used in training, (C) 3-Class LDA, 50% of samples used in training, (D) 3-Class LDA, 95% of samples used in training. Increased probability classi cation threshold increases Q5's percent correctly classi ed, positive predictive value, sensitivity, and speci city while decreasing the percent classi ed. some of the SwissProt and TrEMBL entries are annotated with known or hypothesized function, many of the entries (particularly in the TrEMBL database) are of unknown function (Bairoch and Apweiler, 2000) . While these "lead" proteins have masses consistent with the most signi cant discriminant peaks, we caution that the database lookup does not prove that these proteins are present in the serum. These lead proteins can serve as the starting point for previously described biomarker identi cation protocols. Perhaps the most interesting protein identi ed among those with known function for the OC-WCX2b query is TrEMBL entry 3 Q9BZK8, a 76AA protein of OCR1 (ovarian-cancer-related protein 1). Other interesting results include Q9NPJ2, a 36AA protein fragment of P53/TP52 (cellular tumor antigen); Q9NP09, a 36AA protein fragment of ERBB2 (polymorphism of the HER-2/neu oncogene); Q13262, a 44AA estrogen receptor fragment; Q9UH52/Q96B49, a 74AA protein fragment of OBTP (over-expressed in some breast 
a (A) 50% Training with a 0.63 probability classi cation threshold.
(B) 95% Training with a 0.63 probability classi cation threshold. Average performance is reported with the standard deviation in parentheses. NH: normal healthy; BPH: benign prostatic hypertrophy; PC: prostate cancer.
of TAP1 (tumor associated protein). Approximately 90 of the genes found in the ovarian cancer search and 70 of the genes found in the prostate cancer search have novel or unknown function. This raises the possibility that these genes may have a role or additional roles in ovarian or prostate cancer. The normalized discriminants are shown in Fig. 5 ; the m=z peaks consistent with the masses of the described proteins are indicated.
Other methods for protein identi cation via mass spectrometry have been developed. Three main alternative techniques exist. In the rst, the mass spectrum of a proteolytic digest determines a set of protein fragment masses that can be matched to a database (James et al., 1993) . In the second approach, a peptide's sequence is directly identi ed by tandem mass spectrometry (MS/MS) (Dancik et al., 1999; Pevzner et al., 2000) . In a third approach, tandem mass spectrometry may be applied to a proteolytic digest of the target proteins after these fragments have been separated via chromatography (e.g., liquid chromatography The signi cance vector s is computed as described in Methods (Equation 2). The 400 largest m=z discriminant peaks (absolute value)-the most signi cant peaks for classi cation-were identi ed. A §15 Dalton window around each peak was used to search the SwissProt and TrEMBL protein databases (Bairoch and Apweiler, 2000) . The number of false positive proteins was found to increase with the size of the search window. The search window was selected to account for small posttranslational modi cations while minimizing the number of false positives. Using the database search, Q5 was able to nd a number of proteins and protein fragments with masses consistent with the most signi cant discriminant peaks. The table lists the number of entries in the database that matched our search query. In parentheses are the number of proteins with functional annotations: ovary, ovarian, growth, cancer, carcinoma, tumor, serum, or plasma (for the prostate cancer dataset, prostate was used in place of ovary and ovarian).
FIG. 5.
The normalized discriminant for ovarian dataset OC-WCX2b (top) and prostate dataset PC-IMAC-Cu (bottom) starting at an m=z value of 500. The location of the SwissProt and TrEMBL proteins noted in the text are indicated by their identi cation numbers for each discriminant (see text). These SwissProt and TrEMBL proteins are consistent with m=z peaks of the discriminant having signi cance for classi cation. Due to mass-aliasing, the database look-up does not prove these proteins present in the serum samples, but these proteins can serve as leads in the search for novel biomarkers.
(LC) MS) (Link et al., 1999; Perkins et al., 1999) . In the last two approaches, one may use a database for sequence identi cation, or the peptide sequencing may be done de novo. Currently available whole-serum clinical cancer MS data is neither from a controlled proteolytic digest, nor from tandem mass spectrometry. Hence, we used a different approach to help identify the molecules most important in discrimination. It would be interesting, in future work, to extend Q5 to take advantage of the additional information experimentally available from controlled proteolytic digests or MS/MS. Our work represents the rst attempt to compute the molecular identities of the differentially expressed proteins in datasets OC-WCX2b and PC-IMAC-Cu. Further investigation of our lead proteins and peptide fragments may enhance our understanding of the molecular basis of oncogenisis and could potentially lead to new therapeutic targets. 
CONCLUSION
Mass spectrometry will soon play an important role in both the research lab and hospital clinic. For all but the simplest cases, manual analysis of complete complex spectra is impractical. This observation led to the development of a variety of MSCAs. Of the previous MSCAs, those that use complete complex spectra (Petricoin et al., 2002; Adam et al., 2002) , do not use exact algorithms. Conversely, those MSCAs that are exact (Miketova et al., 2003; Wagner et al., 2002) do not operate on complete complex spectra. In contrast to previous work, Q5 uses PCA and LDA followed by probabilistic classi cation on complete complex SELDI-TOF mass spectra for the classi cation of healthy versus disease serum samples. The use of a probabilistic classi cation framework increases the predictive accuracy of Q5. A tradeoff is shown between con dence in classi cation and the number of samples classi ed. Our solution is computationally ef cient; it is noniterative and computes the optimal linear discriminant using closed-form equations. Q5 thus represents a generally applicable technique. Although Q5 was tested against ovarian and prostate cancer, it is reasonable to hypothesize that Q5 may be effective in the screening of other cancers and diseases. Q5 was tested against two cancer types and four datasets. Our results show that a classi cation threshold can be chosen for Q5 such that over 90% of the samples are classi ed with a sensitivity, speci city, and PPV near 100%. Q5 performed at or above the level of previous techniques while conferring all advantages of a closed-form exact solution. The consistently high level of performance on the testing spectra demonstrates that Q5 was not over-t to the training spectra. We note that Q5's time complexity grows only linearly with the resolution of the mass spectra. Thus, Q5 will scale well as higher-resolution spectra are collected.
Another advantage of Q5 is that the discriminant can be examined both to identify and to support the validity of novel biomarkers. Whereas previous complete complex spectra MSCAs discriminate using a small fraction of the total number of m=z peaks, Q5 computes all peaks that are differentially expressed in one class versus the other. We showed how Q5's discriminant back-projection technique can compute clues as to the molecular identities of differentially expressed proteins and peptides.
Finally, we note that for MSCAs to be practical in a clinical setting, questions of reproducibility must be addressed. Ideally, a discriminant computed from one spectrometer should generalize to classify spectra collected on a different spectrometer, in a different laboratory. We have not addressed such reproducibility questions, which will be important for future work.
APPENDICES
Appendix A. Principal components analysis
Each sample spectrum in the training set is represented as a column vector x (x 2 X; jXj D n x ) (healthy) or y (y 2 Y; jY j D n y ) (disease). Here j ¢ j is the number of elements in the speci ed set. Thus, n x (respectively, n y ) is the number of healthy (respectively, disease) samples. Let n D n x C n y be the total number of training samples; we assume all x and y vectors have dimensionality r (i.e., each mass spectrum is sampled at r points). The all-class mean,
is computed and subtracted from each sample, producing sets of zero-meaned samples X 0 and Y 0 . The columns of the r £ n matrix P consist of all zero-meaned samples,
The r £ r covariance matrix C can then be computed:
The principal components are the eigenvectors, v i , of the covariance matrix C. An eigendecomposition of C produces at most w D min.n; r/ nonzero eigenvalues¸i (i D 1; : : : ; w) with corresponding normalized eigenvectors v i such that Cv i D¸i v i . Each eigenvalue¸i is proportional to the variance of the original data in the direction of the i th principal component. Frequently, the number (r) of points in each sample spectrum greatly exceeds the number (n) of samples. In this case, an alternate formulation of the covariance matrix may be preferable. When r > n, increased computational ef ciency can be achieved by computing the eigenvectors of the n £ n Gram matrix C 0 ,
The eigenvalues of C 0 equal the eigenvalues of C, and the normalized eigenvectors of C 0 (v 0 i , i D 1; : : : ; w) can be related to the normalized eigenvectors of C by
The largest principal components typically account for nearly all sample variance. Therefore, dimensionality reduction with PCA can be accomplished by sorting components by eigenvalue and then discarding the eigenvectors with the smallest corresponding eigenvalues. After discarding the eigenvectors, the w 0 eigenvectors that remain constitute the PCA basis. Once a set of principal components is selected as a basis, sample points can be projected onto these axes,
where the rows of matrix V are the retained eigenvectors v i (i D 1; : : : ; w 0 ), and x p (respectively, y p ) are the PCA-space projections of each healthy (respectively, disease) sample onto the w 0 principal components.
The probability that a discriminant-space point z d (where z d has dimension k ¡ 1) belongs to class C i is
As in the two-class probabilistic framework, a classi cation threshold t 2 [0:5; 1:0] is speci ed such that a classi cation is made if and only if there exists an i such that P .z d 2 C i / > t. If this criterion is not satis ed, we consider z d to be ambiguous, and a classi cation is not made. By construction, it is not possible for a point to be classi ed into more than one class when the classi cation threshold t is chosen in the range [0:5; 1:0]. Note that the variances and classi cation probabilities computed for two classes using either the two-class model or the k-class model (with k D 2) are identical.
SUPPORTING MATERIAL
The MATLAB code for Q5 is available at www.cs.dartmouth.edu/»brd/Bio and by contacting the authors. The software is distributed under the Gnu Public License (Gnu, 2002) .
